Nationwide Fund Advisors Reduces Holdings in AngioDynamics, Inc. (ANGO)

Nationwide Fund Advisors decreased its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 18.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,474 shares of the medical instruments supplier’s stock after selling 20,854 shares during the period. Nationwide Fund Advisors owned about 0.25% of AngioDynamics worth $1,483,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the business. Ameriprise Financial Inc. grew its stake in shares of AngioDynamics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 658,773 shares of the medical instruments supplier’s stock worth $10,679,000 after acquiring an additional 44,052 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of AngioDynamics by 23.7% in the second quarter. TIAA CREF Investment Management LLC now owns 289,160 shares of the medical instruments supplier’s stock worth $4,687,000 after acquiring an additional 55,444 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of AngioDynamics by 9.0% in the second quarter. Teachers Advisors LLC now owns 84,021 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 6,928 shares in the last quarter. NorthCoast Asset Management LLC acquired a new position in shares of AngioDynamics in the second quarter worth $966,000. Finally, Martingale Asset Management L P grew its stake in shares of AngioDynamics by 3.9% in the second quarter. Martingale Asset Management L P now owns 217,968 shares of the medical instruments supplier’s stock worth $3,534,000 after acquiring an additional 8,104 shares in the last quarter. Institutional investors and hedge funds own 95.42% of the company’s stock.

AngioDynamics, Inc. (NASDAQ ANGO) opened at 17.69 on Friday. The firm has a 50 day moving average of $17.43 and a 200 day moving average of $16.38. The firm has a market cap of $649.49 million, a P/E ratio of 178.69 and a beta of 1.12. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The business had revenue of $85.40 million during the quarter, compared to analysts’ expectations of $86.12 million. During the same period in the prior year, the business posted $0.17 EPS. The business’s revenue was down 3.1% on a year-over-year basis. On average, equities research analysts expect that AngioDynamics, Inc. will post $0.66 EPS for the current year.

WARNING: “Nationwide Fund Advisors Reduces Holdings in AngioDynamics, Inc. (ANGO)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/20/nationwide-fund-advisors-reduces-holdings-in-angiodynamics-inc-ango.html.

Several equities analysts have commented on ANGO shares. Cantor Fitzgerald boosted their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. Canaccord Genuity restated a “hold” rating and issued a $17.00 price target on shares of AngioDynamics in a research note on Tuesday, July 18th. Barclays PLC dropped their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. Zacks Investment Research

Several other large investors have also bought and sold shares of the business. Ameriprise Financial Inc. grew its stake in shares of AngioDynamics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 658,773 shares of the medical instruments supplier’s stock worth $10,679,000 after acquiring an additional 44,052 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of AngioDynamics by 23.7% in the second quarter. TIAA CREF Investment Management LLC now owns 289,160 shares of the medical instruments supplier’s stock worth $4,687,000 after acquiring an additional 55,444 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of AngioDynamics by 9.0% in the second quarter. Teachers Advisors LLC now owns 84,021 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 6,928 shares in the last quarter. NorthCoast Asset Management LLC acquired a new position in shares of AngioDynamics in the second quarter worth $966,000. Finally, Martingale Asset Management L P grew its stake in shares of AngioDynamics by 3.9% in the second quarter. Martingale Asset Management L P now owns 217,968 shares of the medical instruments supplier’s stock worth $3,534,000 after acquiring an additional 8,104 shares in the last quarter. Institutional investors and hedge funds own 95.42% of the company’s stock.

AngioDynamics, Inc. (NASDAQ ANGO) opened at 17.69 on Friday. The firm has a 50 day moving average of $17.43 and a 200 day moving average of $16.38. The firm has a market cap of $649.49 million, a P/E ratio of 178.69 and a beta of 1.12. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The business had revenue of $85.40 million during the quarter, compared to analysts’ expectations of $86.12 million. During the same period in the prior year, the business posted $0.17 EPS. The business’s revenue was down 3.1% on a year-over-year basis. On average, equities research analysts expect that AngioDynamics, Inc. will post $0.66 EPS for the current year.

WARNING: “Nationwide Fund Advisors Reduces Holdings in AngioDynamics, Inc. (ANGO)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/20/nationwide-fund-advisors-reduces-holdings-in-angiodynamics-inc-ango.html.

Several equities analysts have commented on ANGO shares. Cantor Fitzgerald boosted their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. Canaccord Genuity restated a “hold” rating and issued a $17.00 price target on shares of AngioDynamics in a research note on Tuesday, July 18th. Barclays PLC dropped their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. Zacks Investment Research downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. AngioDynamics has an average rating of “Hold” and an average price target of $18.60.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply